Dr. Filipa Lynce, MD

Dr. Filipa Lynce, MD

Languages: English (Primary Language), French (Fluent), Portuguese (Fluent), Spanish (Fluent)
Fax: (202) 444-1229

Contact this Provider:

  • Hematology Oncology (Primary); certified in 2014
Clinical Areas of Focus
  • Breast Cancer
About the Provider

I am a medical oncologist with expertise in caring for patients with breast cancer. I obtained my medical degree at Universidade Nova de Lisboa in my home country, Portugal. After that, I moved to the U.S. to continue my training, and I completed my residency and fellowship in Washington D.C., at MedStar Washington Hospital Center. My primary clinical and research interest is in novel therapies and clinical trials for breast cancer, triple negative breast cancer, health disparities, and cancer genetics.

During my training, I developed a clinical trial to evaluate the cardiac safety of HER2 targeted therapies in patients with mildly reduced cardiac function for which I received a Young Investigator Award from the Conquer Cancer Foundation/Breast Cancer Research Foundation. My other projects have focused on studying deleterious BRCA1/2 mutations in African American women who underwent genetic testing for hereditary breast-ovarian cancer and the cardiac toxicity of anthracyclines in women with BRCA1/2 mutations. I am optimist about the future of patients diagnosed with breast cancer as we learn more about the different subtypes of the disease and new drugs with meaningful impact in our patients lives become available.

  • Fellowship Program: MedStar Washington Hospital Center (2014)
  • Residency Program: MedStar Washington Hospital Center (2011)
  • Medical School: Universidade Nova de Lisboa, Portugal (2004)
  • Journal - 06/12/2014
    HER2-targeted therapies have revolutionized the outcome of patients with HER2-positive breast cancer. Pertuzumab is the first in a new class of monoclonal antibodies that target the extracellular dimerization domain of HER2 receptors, also known as HER dimerization inhibitors. The development of pertuzumab and preclinical and clinical data in breast cancer are reviewed. Regulatory affairs related to pertuzumab and the recent accelerated approval granted by the FDA for the treatment of breast cancer in the neoadjuvant setting are also covered. This process opens doors for further approvals which could considerably shorten the time between initial drug development and availability.
  • Journal - 12/12/2012
    Post-transfusion purpura is a rare immunohematological disorder characterized by severe thrombocytopenia following transfusion of blood components and induced by an alloantibody against a donor platelet antigen. It occurs primarily in women sensitized by pregnancy and is most commonly caused by anti-human platelet antigen-1a antibodies. Here, we describe what we believe to be the first documented case of an African-American man who developed post-transfusion purpura due to an anti-human platelet antigen-5b alloantibody after receiving multiple blood products.
  • Journal - 02/13/2012
    Angiogenesis is an essential requirement for the growth of solid tumors and the inhibition of the angiogenic pathway has become an important therapeutic target. Bevacizumab (Avastin, Genentech), a monoclonal antibody against vascular endothelial growth factor (VEGF), was the first antiangiogenic drug to demonstrate a survival benefit in cancer patients. Initially approved by the Food and Drug Administration (FDA) in 2004 as first-line treatment for metastatic colon cancer, bevacizumab was then designated as 'the fourth modality for cancer treatment'.
  • Journal - 04/15/2012
    As a result of therapeutic advances, survivors of lymphoma are now living longer. However, their mortality is higher when compared to the general population, probably due to multiple factors. Survivors of childhood leukemia and lymphoma appear to have an increased prevalence of obesity. The objectives of this retrospective study were to analyze weight change after lymphoma treatment in an adult population and determine factors predictive of weight gain. Data were collected from 219 patients and analyzed sequentially at the initial visit and at 6, 12 and 18 months. There was a progressive increase in weight from the initial visit to 6 months (1.5% increase of initial body weight), 12 months (4.5%) and 18 months (6.4%). More than 9% of patients experienced weight gain greater than 20% during follow-up. There was a statistically significant association between the percentage of increase in weight and age, B symptoms and body mass index (BMI) at presentation. Younger patients, those with B symptoms or those with lower BMI manifested more weight gain (p = 0.0008, p = 0.0440 and p = 0.0009, respectively). Other assessed factors had no effect on weight gain including sex, race, lymphoma histology, disease outcome, radiation therapy, number of treatment regimens and use of steroids. Further studies are needed to explore long-term weight trends and their impact on the health of lymphoma survivors.
  • Journal - 10/31/2008
    The progress made over the last years has turned cancer into a potentially curable, or at least, chronic disease. Thus, our concern moves towards toxicity. While some years ago cardiotoxicity was an issue mainly in children with leukemia treated with anthracyclines, today it has become a significant problem for many others. Moreover, a prolonged survival allows more time for the use of different potentially cardiotoxic agents as well as radiotherapy.
Professional Memberships
  • American Society of Clinical Oncology

2013 - Young Investigator Award Conquer Cancer Foundation/American Society of Clinical Oncology

2013 - Lynn Sage Breast Cancer Achievement Award

2011 - Best Resident, Peer Recognition Award, MedStar Georgetown University Hospital/MedStar Washington Hospital Center Internal Medicine Residency Program

2009 - Best Intern 2008-2009, Peer Recognition Award, MedStar Georgetown University Hospital/MedStar Washington Hospital Center Internal Medicine Residency Program

Member of Medical Staff
  • MedStar Georgetown University Hospital
  • MedStar Washington Hospital Center